## Nova Scotia Provincial Pharmacare Programs Request for Coverage of Prasugrel

PATIENT INFORMATION			
PATIENT SURNAME	PATIENT GIVEN NAME	HEALTH CARD NUMBER	DATE OF BIRTH
PATIENT ADDRESS			
In combination with ASA for patients with:			
Unstable angina (UA) or non-ST-segment elevation myocardial infarction (NSTEMI) managed with percutaneous coronary intervention (PCI)			
Date of PCI:			
<u>OR</u>			
☐ ST-segment elevation myocardial infarction (STEMI) managed with primary or delayed PCI			
Date of PCI:			
<u>OR</u>			
☐ Failure on clopidogrel and ASA therapy as defined by definite stent thrombosis¹, or recurrent STEMI, NSTEMI or UA after revascularization with PCI.			
Date of event:			
<ol> <li>Definite stent thrombosis, according to the Academic Research Consortium, is a total occlusion originating in or within 5 mm of the stent or is a visible thrombus within the stent or is within 5 mm of the stent in the presence of an acute ischemic clinical syndrome within 48 hours.</li> </ol>			
Comments (if applicable):			
PRESCRIBER NAME & ADDRESS:			
_	LICENCE # PRESCRI	BER SIGNATURE DA'	TE

If you need assistance, please contact the Pharmacare Office at (902) 496-7001 or 1-800-305-5026

Please Return Form To: Nova Scotia Pharmacare Programs

P.O. Box 500, Halifax, NS B3J 2S1

Fax: (902) 496-4440

